APA (7th ed.) Citation

de Wild, S. R., de Munck, L., Simons, J. M., Verloop, J., van Dalen, T., Elkhuizen, P. H. M., . . . Boersma, L. J. (2022). De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study. The lancet oncology, 23(9), 1201-1210. https://doi.org/10.1016/S1470-2045(22)00482-X

Chicago Style (17th ed.) Citation

de Wild, Sabine R., et al. "De-escalation of Radiotherapy After Primary Chemotherapy in CT1–2N1 Breast Cancer (RAPCHEM; BOOG 2010–03): 5-year Follow-up Results of a Dutch, Prospective, Registry Study." The Lancet Oncology 23, no. 9 (2022): 1201-1210. https://doi.org/10.1016/S1470-2045(22)00482-X.

MLA (9th ed.) Citation

de Wild, Sabine R., et al. "De-escalation of Radiotherapy After Primary Chemotherapy in CT1–2N1 Breast Cancer (RAPCHEM; BOOG 2010–03): 5-year Follow-up Results of a Dutch, Prospective, Registry Study." The Lancet Oncology, vol. 23, no. 9, 2022, pp. 1201-1210, https://doi.org/10.1016/S1470-2045(22)00482-X.